Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) – Analysts at Leerink Swann raised their FY2019 earnings per share (EPS) estimates for shares of Sucampo Pharmaceuticals in a research report issued on Monday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will earn $1.79 per share for the year, up from their prior estimate of $1.65. Leerink Swann has a “Market Perform” rating and a $15.00 price objective on the stock. Leerink Swann also issued estimates for Sucampo Pharmaceuticals’ FY2020 earnings at $2.02 EPS and FY2021 earnings at $2.19 EPS.

A number of other analysts also recently issued reports on the stock. Nomura initiated coverage on shares of Sucampo Pharmaceuticals in a report on Monday, December 18th. They issued a “buy” rating and a $43.00 price objective for the company. ValuEngine upgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, December 7th. initiated coverage on shares of Sucampo Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $14.00 target price for the company. BidaskClub upgraded shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 5th. Finally, Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Six investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $21.58.

Sucampo Pharmaceuticals (NASDAQ SCMP) traded down $0.10 during midday trading on Wednesday, reaching $18.05. 6,048,610 shares of the company’s stock were exchanged, compared to its average volume of 4,786,277. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The company has a market cap of $841.80, a P/E ratio of -5.39, a P/E/G ratio of 5.04 and a beta of 1.45. Sucampo Pharmaceuticals has a 52-week low of $9.30 and a 52-week high of $18.20.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.30 EPS.

In other news, insider Peter A. Kiener sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $16.50, for a total value of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares in the company, valued at approximately $858,379.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.13% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Krensavage Asset Management LLC increased its position in Sucampo Pharmaceuticals by 0.6% during the 2nd quarter. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company’s stock worth $29,607,000 after purchasing an additional 16,570 shares in the last quarter. LSV Asset Management increased its position in Sucampo Pharmaceuticals by 1.9% during the 2nd quarter. LSV Asset Management now owns 2,390,418 shares of the biopharmaceutical company’s stock worth $25,099,000 after purchasing an additional 44,000 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Sucampo Pharmaceuticals during the 3rd quarter worth approximately $21,989,000. Vanguard Group Inc. increased its position in Sucampo Pharmaceuticals by 13.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock worth $17,287,000 after purchasing an additional 189,561 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock worth $16,487,000 after purchasing an additional 15,528 shares in the last quarter. Institutional investors and hedge funds own 65.29% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Post FY2019 Earnings of $1.79 Per Share” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/05/sucampo-pharmaceuticals-inc-scmp-expected-to-post-fy2019-earnings-of-1-79-per-share.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.